neuronal populations, including those that are aff ected by neurodegeneration in Alzheimer's disease (AD). NGF maintains the survival of cholinergic neurons of the basal forebrain system, nociceptive dorsal root ganglion neurons and some third-order sympathetic neurons, while BDNF supports cholinergic, dopaminergic neurons as well as those containing 5-hydroxytryptamine and neuropeptides. NT-3 was shown to prevent the death of adult central noradrenergic neurons in vivo [1] [2] [3] [4] . In AD the primary regions aff ected are the hippocampus, cerebral cortex and amygdala. Neuronal loss involves in particular the cholinergic neurons of the basal forebrain system and those of the noradrenergic and serotonergic system. NGF promotes survival of those neurons by activating its specifi c high-affi nity tyrosine kinase receptor TRKA, while downstream of TRKA, the small G-protein p21ras plays a pivotal role in controlling neuronal survival and diff erentiation. We have shown that in AD brain TRKA expression is downregulated [5] [6] [7] . Various reports also demonstrated increased levels of NGF in cortical and subcortical brain areas including the frontal and parietal cortices and the hippocampus. Th ese increases were attributed to both reduced uptake and retrograde transport of NGF to NGFsensitive cell bodies, since the expression and protein levels of TRKA were reduced in target regions of basal fore-
Introduction
Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the neurotrophin (NT) gene family that supports the survival of specifi c brain cholinergic neurons, such as the cortical association areas. Of particular interest is the increased expression of proNGF in AD subjects as it is considered to mediate a pro-apoptotic signal through the activation of the NT receptor p75 NTR [8] [9] [10] . In contrast, BDNF messenger RNA levels were reported to be lowered in hippocampal neurons and protein levels decreased in the entorhinal and parietal cortex of patients with AD. Th ese results point to an antagonistic involvement of NGF and BDNF, both of which are associated with trophic support of cholinergic neurons of the basal forebrain system, in the neuropathology of AD.
AD is the most common cause of dementia among people of age 65 and older. It is a progressive neurodegenerative disorder characterized by impaired memory and cognition. Th e treatment of AD remains a major challenge because of the incomplete understanding of triggering events that lead to the selective neurodegeneration characteristic of AD brains. In the past decade it has become evident that the clinical and histopathological phenotypes of AD are caused by heterogenous genetic and possibly environmental factors. Several genes, including amyloid precursor protein (APP), presenilin-1 (PS-1) and PS-2, have been identifi ed as the possible cause of most familial forms of the disease. Although several genetic defects have been identifi ed in patients with a family history of this disease, the majority of AD cases has a late-onset (over the age of 65) and involves individuals with no known genetic predisposition. One major genetic risk factor for the disorder in the typical late-onset period was provided by the discovery of the predisposition of the ε4 allele of apolipoprotein E (ApoE) to AD. Inheritance of one or two ε4 alleles increases the likelihood of developing AD and makes its mean age of onset earlier than in subjects harboring ε2 or ε3 alleles [11] [12] [13] [14] . Th e disease is characterized by the presence of neuritic amyloid plaques, cerebrovascular amyloidosis and neurofi brillary tangles (NFTs). Th e AD brain exhibits extracellular plaques of aggregated amyloid-␤ -peptide (A ␤ ) and intracellular NFTs containing hyperphosphorylated TAU protein. Usually, the hippocampal area, perforant path, and entorhinal cortex exhibit NFTs earliest in the course of AD. Among cortical association areas, the parietal cortex shows deposition of A ␤ plaques, NFTs, and neuronal loss earlier than the frontal cortex, whereas the cerebellum is usually preserved. A ␤ is generated from its APP via sequential proteolytic cleavages by ␤ -and ␥ -secretases. It is widely believed that the A ␤ plaques are the primary cause of neurotoxicity and subsequent neuronal cell death in the brains of AD patients [11] [12] [13] [14] .
For decades, scientists investigating APP have focused on its pathogenic role in the brains of AD patients because the prevalence of the A ␤ toxicity theory in AD pathology tends to limit the focus of research on its pathophysiological function. As such, the physiological role of APP is still not well understood. However, based on its sequence conservation throughout evolution, it is likely that APP has important functions to fulfi ll. Understanding these functions of APP would contribute towards a better understanding of the molecular pathogenesis of AD, and ultimately facilitate the design of therapeutic strategies. Studies show that APP is conserved among mammalian species, and homologues have been identifi ed in human (APLP1, APLP2), mouse, Drosophila melanogaster and Caenorhabditis elegans [15] [16] [17] . Its conservation throughout evolution suggests that APP plays an important role in brain function in vivo. For instance, APP is a mediator of neurite outgrowth, and may be involved in neural development and synaptic plasticity [18] . Th e function of APP is probably dispensable for mouse embryogenesis and development, since APP knockout mice were able to survive to birth. Alternatively, its function could be compensated for by APP homologues. However, APP's implication in intra-neuronal calcium regulation and G-protein signaling events may explain the observation obtained from APP knockout studies showing age-related cognitive defi cits due to impaired long-term potentiation. Th is indicates that APP, and most probably A ␤ are indispensable components for higher brain function [19] [20] [21] [22] [23] .
APP is expressed abundantly by almost all cells and is present in high amounts in neurons of the central nervous system (CNS). Alternative splicing generates several isoforms of APP of which APP 695 is expressed predominantly in neurons [24, 25] . Th e expression of APP resembles that of a typical housekeeping gene, and can be found in a variety of organs [26] . In the CNS, APP is widely distributed and exists in the cytoplasm, dendrites and axons of the neurons [27] . Several roles have been proposed for APP in this region.
APP undergoes at least three diff erent processing pathways. In the constitutive secretory pathway, APP is cleaved by a membrane-associated ␣ -secretase within the A ␤ domain, releasing the soluble extracellular domain of APP (sAPP ␣ ). Th is pathway is non-amyloidogenic because the cleavage precludes the formation of A ␤ [28] . In the alternative pathway, APP is fi rst cleaved in the extracellular domain by the ␤ -site APP-cleaving enzyme BACE1, followed by a ␥ -secretase cleavage within the transmembrane domain of the stub generated by ␤ -cleavage, liberating the 39-43 amino acid A ␤ peptide. Concurrent ε-site 3 cleavage generates the APP intracellular domain (AICD) fragment which translocates to the nucleus and acts as a signaling molecule involved in transcriptional activation [29] [30] [31] [32] . However, neither the intermediate A ␤ peptide, which ends at the ε-cleavage site, nor the C-terminal fragment starting with an N-terminus generated by ␥ -cleavage, has ever been detected. One possibility is that ␥ -and ε-cleavages occur simultaneously. Th e other possibility is that there may be additional cleavages between the ␥ -and ε-cleavages. Indeed, the new cleavage site identifi ed at A ␤ 46 was designated as the -cleavage site. It is also noted that the new -cleavage site at A ␤ 46 is the APP717 mutation site. Th e new cleavage is within the transmembrane domain and a Presenilin-dependent event [33] .
While the protein complex, consisting of Presenilin, Nicastrin, Pen2 and Aph1, controls the ␥ -cleavage site of APP, the Reticulons indirectly control the ␤ -cleavage site of APP via interaction with BACE. An increase in the Reticulon protein reduces the production of A ␤ . Th e other protein Alcadein (Alc) forms a protein complex with APP and X11L (X11L, also known as the APP-binding-family-A-member-2 (APBA2)), thereby regulating APP metabolism and suppressing A ␤ production. Th e metabolism of Alc resembles that of APP including the Presenilin-dependent ␥ -cleavage mechanism. In addition to the eff ect of mutations in Presenilin or APP, any imbalance in the metabolism of Reticulon, Alc and APP may infl uence the Fe65-dependent gene transactivation, which together with increased secretion of A ␤ may contribute to neurodegeneration in AD [14] .
Th e A ␤ peptide is a normal product of cells [34, 35] . Around 90% are A ␤ 40 , a fairly soluble form of the peptide; the remaining are A ␤ 42 and A ␤ 43 peptides which are highly fi brillogenic, and are deposited selectively in amyloid plaques [36] [37] [38] . Under normal conditions, the concentration of A ␤ is tightly controlled by degradation enzymes and maintained below the threshold for aggregation into ␤ -sheet fi brils [39] . Recent discoveries show that A ␤ , while toxic and AD causing if overproduced, has a physiological and non-toxic function. It regulates cellular lipid levels. In specialized regulatory cycles A ␤ controls the cholesterol synthesis by lowering hydroxymethylglutarylCoA reductase activity and sphingomyelin levels. Th ese lipids control the activity of the enzyme producing A ␤ , resulting in altered A ␤ levels. Interference with these regulatory cycles by pharmacological, genetic, or even dietary means, changes A ␤ production and thus the risk for AD. Knowledge of the physiological function of A ␤ allows us to reevaluate the therapeutic and preventive approaches and to generate more specifi c and novel therapies for the treatment of AD. It also explains the functional link between AD and cholesterol and how statins (cholesterollowering drugs) work to prevent AD [35] .
Th e net accumulation of A ␤ peptides (especially the amyloidogenic A ␤ 42 isoform) plays a central role in the pathogenesis of AD, and likely refl ects the cumulative effect of multiple events, including the abnormal regulation and misprocessing of APP. Th e accumulation of A ␤ initiates a series of downstream neurotoxic events, such as impairment of membrane transporters, destabilization of cellular calcium homeostasis, and the hyper-phosphorylation of TAU, resulting in neuronal dysfunction and death [11, 12, 14, 36] .
Despite advances in our understanding of the basic biological roles of APP, the normal physiological functions of APP in learning and memory still remain unclear. It has been proposed that changes in the activity of the diff erent A ␤ fragments as a result of altered APP processing during the course of AD may also contribute to cognitive dysfunction. With these new developments researchers are now focusing more on elucidating the physiological actions of soluble A ␤ , and the normal functions performed by APP in the brain. A ␤ exhibits the capacity to exert powerful regulatory control over key neural functions including cell excitability, synaptic transmission and longterm potentiation, both acutely and over the long-term for neural plasticity [14, 40, 41] . For instance, a recent report has proposed a negative feedback model in which the activity-dependent modulation of A ␤ production participates in keeping neuronal hyperactivity under control. In this model neural activity regulates ␤ -secretase actions on APP. Th us, neuronal activity regulates the production and secretion of A ␤ by controlling APP processing upstream of ␥ -secretase activity. Moreover, while the formation of A ␤ depresses synaptic transmission, synaptic depression decreases neural activity. Any disturbance in this feedback loop may contribute to an increase in A ␤ formation and neuronal toxicity in AD [41] .
AD and the NGF System
Neurotrophic factors have attracted much attention regarding their potential as a remedy for neurological disorders. In this regard, NGF has generated great interest as a potential target for the treatment of AD. Th is interest is based on the observation that cholinergic neurons of the basal forebrain (CBFs), which provide the major source of cholinergic innervation to the cerebral cortex and hippocampus, undergo selective and severe degeneration in ad- . Dysfunction of NGF and its high (TRKA) and low (p75 NTR ) affi nity receptors has been suggested to underlie the selective degeneration of the nucleus basalis (NB) cholinergic cortical projection neurons in the end stage of AD. Whether the NGF system is dysfunctional during the prodromal stages of AD has only recently been evaluated [5] [6] [7] [8] [9] [10] [42] [43] [44] [45] . Surprisingly, the number of neurons containing choline acetyltransferase (ChAT, enzyme-synthesizing neurotransmitter acetylcholine) remains stable despite a signifi cant reduction in NGF receptor-positive cells in people with mild cognitive impairment. Th is suggests a phenotypic NGF receptor downregulation but not an obvious loss of NB neurons during prodromal AD. Furthermore, there is an increase in proNGF levels (precursor of mature NGF) and a loss of cortical TRKA in the face of stable p75
NTR (which has a high affi nity for proNGF and may convey a pro-apoptotic signal [8] ) during the early stage of AD. Depending on the cellular context these changes may result in increased pro-apoptotic signaling, cell survival, or a defect in retrograde transport mechanisms [14] . Alterations in NGF and its receptors within the cholinotrophic NB system in early AD suggest that NGF-mediated cell signaling is required for the long-term survival of these neurons. Th erapeutic neurotrophic intervention might delay or prevent NB neuron degeneration and preserve cholinergic cortical function during prodromal AD [42] [43] [44] [45] . With regard to these fi ndings, it is interesting to mention that an anti-NGF-antibody animal model shows typical features of AD [46] [47] [48] . Th e aged anti-NGF transgenic mice acquire an age-dependent neurodegenerative pathology including amyloid plaques, insoluble and hyperphosphorylated TAU, and NFTs in cortical and hippocampal neurons. Extensive neuronal loss throughout the cortex and cholinergic defi cits in the basal forebrain were also observed as well as behavioral defi cits. Th e recognition memory defi cits in these transgenic mice were then shown to be rescued by administering intranasal NGF [49] . Th ese results demonstrate that a defi cit in the signaling and transport of NGF leads to neurodegeneration. Th e overall picture is strikingly reminiscent of human AD.
APP and NGF Signaling
One of the more interesting aspects of APP is its function as a kinesin-I membrane receptor mediating the axonal transport of cargo proteins such as BACE, PS-1, GAP43, synapsin, the 'Sunday-driver' SYD and TRKA [50] [51] [52] [53] [54] . Th e carboxy-terminus mediates binding of APP to the motor protein (kinesin light chain of kinesin-I), whereas the A ␤ region might be an essential part of the sorting signal for axonally transported vesicles [50] [51] [52] 55] . Th is raises the possibility that axonal damage might induce APP proteolysis to release the AICD, which might then transmit an injury signal to the cell body where it relocalizes to the nucleus mediating gene transcription via (direct or indirect) interaction with Fe65, 14-3-3 ␥ , Tip60 (a histone acetyltransferase) and CP2 ( ␣ -globin transcription factor, also known as LSF or LBP-1) [30, [56] [57] [58] [59] .
APP seems to be directly involved in regulating apoptotic signaling pathways through its interaction with the 'Sunday-driver' SYD (also known as JSAP1 or JIP3) and JIP1b/2 because SYD acts as a scaff olding protein for the JNK/MAPK (c-Jun N-terminal kinase, mitogen-activated kinase) cascade and the SYD-JNK3 pathway has been shown to be required for signaling upon nerve injury and stress-induced neuronal apoptosis [54, [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] . Corroborating data confi rmed that mutations in APP connect pro-apoptotic APP-signaling with the JNK pathway [69, 71] .
Another exciting discovery is the modulation of APP phosphorylation by the NGF receptor TRKA ( fi g. 1 ) to couple APP via the Shc/Grb2 adaptor proteins to cellular pathways generally associated with proliferation and survival, including the Ras/MAPK pathway and the PI3K/ PKB (phosphatidylinositol 3-kinase, protein kinasese-B) signal transduction cascade [72] [73] [74] [75] . Th us, considering the fact that the NGF-TRKA system is functionally disturbed in AD [5] [6] [7] [8] [9] [10] [42] [43] [44] [45] , an impaired NGF-TRKAsignaling cascade may aff ect APP transport and signaling, thereby mediating apoptosis via: (i) a retrograde transport of AICD; (ii) the SYD-activated JNK/p38MAPK pathway, or (iii) an inhibited ras/MAPK-PI3K signaling. A deregulation of intracellular transport mechanisms caused by a deteriorated APP/TRKA-NGF-signaling cascade might be one crucial aspect for the initiation of neurodegeneration in AD. Recent results on the anterograde and retrograde transport of NTs will probably help to intensify studies about APP-mediated signaling mechanisms [76] [77] [78] .
In addition to the APP-TRKA interaction, the NGF and the APP systems show a special interplay between A ␤ and p75 NTR . While NT-activated p75 NTR is able to mediate an anti-or pro-apoptotic signal, the A ␤ -p75 NTR signal transduction pathway and its impact on AD are still unsolved problems [8, [79] [80] [81] [82] [83] [84] [85] NTR is processed by a ␥ -secretase enzyme in a similar way to APP, releasing p75ICD to transmit a signal to the nucleus ( fi g. 1 ). Another interesting aspect is the involvement of p75 NTR in triggering small GTP-binding protein-signaling pathways and the activation of Gproteins by APP as revealed by recent fi ndings [8] . Although the downstream eff ects of G o by APP are completely unknown, the signifi cance of G-proteins in directing neural activity and synaptic plasticity is well established and there are various possible ways in which APP-mediated G-protein regulation could infl uence higher cognitive functions [22, 23, 86] . Th us, for our understanding of neurodegenerative processes in AD we need an enlightenment of the physiological role of APP and its processed products AICD and A ␤ . Moreover, the cross-talk among APP's and NGF-receptor's signaling cascades will be an interesting topic for further explorations.
AD and Neural Stem Cells
In recent years it has been noted that the adult brain has the 'self-repair capacity' to replace lost neurons in several selected regions of the CNS, such as the olfactory bulb, hippocampus, adult human subependymal zone and the cortex. Active neurogenesis occurs in the subgranular zone (SGZ) of the hippocampal dentate gyrus, and in the subventricular zone (SVZ) of the lateral ventricles. Neural stem cells (NSCs) within these neurogenic regions can proliferate and diff erentiate into neurons or glia, providing a reservoir for replacement of cells lost during normal cell turnover and aft er brain injury. Neurogenesis involves the self-renewal and proliferation of NSCs, as well as its differentiation into neurons and glia. Newborn neurons and glia then migrate to appropriate regions in the brain, and integrate into neuronal circuits [87] [88] [89] [90] [91] [92] [93] . Neurogenesis comprises diff erent stages, including cell proliferation, mi- gration and diff erentiation which are tightly regulated by both intrinsic and extrinsic factors [94] . It plays important roles in adaptive responses to environmental demands, and is implicated in the learning and memory processes as well as recovery from injury which suggests that abnormalities in neural precursor cells may contribute to the pathogenesis of cognitive disorders such as AD [95] . Recent fi ndings show that impairment of neurogenesis is suffi cient to deteriorate learning and memory in rodents, hinting at a role played by abnormalities in the proliferation and diff erentiation of NSCs in the pathogenesis of disorders in learning and memory such as those in AD [96] .
In the early stages of AD there is a relatively discrete population of neurons aff ected. Th us, the disease off ers a relatively discrete target for potential therapies making it an ideal target for cell replacement therapy using endogenously activated NSCs. Estimations of the number and proliferative capacity of these cells suggest that mobilizing endogenous stem cells already present in the brain or transplantation of exogenous cells to replace lost cells, may be a realistic therapeutic approach. Th e question facing modern medicine is how best to use NSCs to produce functional recovery in neurodegenerative disorders in the aging brain [88, 90, 91, 93] .
Preliminary evidence indicates that NSCs may play a role in the pathogenesis of AD. For instance, A ␤ inhibits proliferation, promotes apoptosis of human cortical stem cells in culture and impairs neurogenesis which is found to be altered in the brains of AD patients. Accumulation of aggregated A ␤ can impair cortical neurogenesis in the AD brain, where neuronal diff erentiation of NSCs is all the more essential for the replacement of degenerating neurons. Th erefore, in addition to synaptic dysfunction and death of mature neurons, this reduced production of new neurons from NSCs within neurogenic niches of the AD brain may contribute to the pathogenesis of the disease. Th us, proliferation and migration in the SVZ is disrupted by the A ␤ peptide, as indicated by in vivo studies in mice [97, 98] . Targeting NSCs as a therapeutic approach for the treatment of AD remains a challenging exercise. With regard to AD, a thorough investigation has already shown that a mixture of epidermal growth factor (EGF), basic fi broblast growth factor (bFGF), retinoic acid and NGF can infl uence proliferation, migration, and phenotype lineage of stem cells in the brain of adult animals with a selective lesion of cholinergic neurons in the basal forebrain. Other than an increase in proliferation in the SVZ, authors could also demonstrate elevated ChAT activity in the hippocampus accompanied by an improved water maze test performance of those mice [99] . Th e data obtained by Haughey et al. [97, 98] show that A ␤ inhibits proliferation and migration of NSCs. However, recent data also suggest that A ␤ does not impair the neurogenic rate in NSC progeny, but instead increases the total number of neurons in vitro. Neurogenesis is induced by A ␤ 42 but not by A ␤ 40 and the neurogenic eff ect of A ␤ is not dependent on soluble factors released from the NSC progeny. Th ese results suggest that A ␤ may have positive as well as deleterious actions, and that knowledge of the mechanisms involved in the former could be valuable in preventing and treating AD [100] [101] [102] . If a general feature of AD is the loss of proliferation of NSCs, then loss of proliferation in the SGZ of the hippocampus may contribute to the observed loss of memory in AD. Th is is suggested by the decreased proliferation of neural precursors in models of AD caused by the A ␤ peptide, which may be exacerbated by the general loss of proliferation in the SGZ associated with aging. However, the exact role of NSCs in AD has yet to be elucidated [91, 100, 103, 104] .
Several fi ndings have also hinted at the involvement of APP itself in the regulation of neurogenesis. It has been reported that APP may act as an autocrine factor to stimulate cell proliferation, and is also able to mediate the effects of NGF on neurite outgrowth [18] . Recent studies have implicated sAPP ␣ , the secreted N-terminal non-amyloidogenic form, as a cofactor of EGF in the stimulation of responsive NSCs in the SVZ of the adult brain [105, 106] . In addition, it has been reported that excess APP in the environment causes glial diff erentiation of stem cells [103] . Th ese fi ndings create the possibility that APP itself may be involved in the regulation of neurogenesis that contributes to normal brain functions. Th is suggests that changes in the levels of APP could have a similar infl uence on the activity of neurogenic regions of the adult brain and that sAPP ␣ plays an important active role in neurogenesis. recovery by producing trophic factors that induce survival and regeneration of host neurons [99, [107] [108] [109] .
However, as of present, the increase in cell proliferation and diff erentiation into mature phenotypes has been described in very few experimental models of neurodegenerative diseases. For instance, in ischemic lesions, a transient and regional specifi c increase has been demonstrated in cell proliferation in the SVZ, cerebral cortex and hippocampus, where newly generated cells diff erentiate into a neuronal phenotype. But the effi ciency of this cell replacement is limited, because the majority of newly generated neurons die shortly aft er generation [110] . Even endogenous NSCs seem to be unable to react in diff erent experimental conditions involving lesions to selective neural populations; transplantation of NSCs at sites of neuronal degeneration is a very promising approach for the treatment of diff erent neurological diseases such as AD [91, 100, 103, 104] .
Previously it has been shown that BDNF can promote survival, but not diff erentiation, of neurons arising from the forebrain subependymal zone [111] . Conversely, BDNF has been reported to enhance both survival and diff erentiation of neurons derived from EGF-responsive postnatal hippocampal stem cells [112] . NGF, in conjunction with bFGF, stimulates proliferation of striatal precursor cells [113] .
Purifi ed SVZ cells express not only the NTs but also their receptors p75 NTR , TRKB and TRKC, but probably no TRKA [109] . Application of exogenous NTs, including NGF, BDNF, and NT-3, to these cells stimulates dendrit- NTR during neural stem cell diff erentiation. ChAT = Choline acetyltransferase; GalC = galactocerebroside; GFAP = glial fi brillary acidic protein; MAP2 = microtubule-associated protein-2; n = nucleus; TH = tyrosine hydroxylase. While NGF and BDNF promote the diff erentiation into neurons and astrocytes via the activation of the p75 NTR and the TRKA/B receptors, NT-3 promotes rather the diff erentiation into the neuronal/oligodendrocyte lineage. 8 ic growth and leads to complex dendritic arbors during the initial 3 days in culture. Th ese studies seem to suggest that the eff ects are mediated by the p75 NTR -activated signaling pathways rather than via the TRK receptors. BDNF is the only NT that is able to infl uence late-phase dendritic development via activation of its specifi c upregulated TRKB receptor. Th us dendritic arbor development of SVZ-derived neuronal cells may be regulated by NTs through the activation of p75 NTR and the TRKB receptor signaling pathways in a sequentially defi ned temporal pattern [109] . Of particular interest is the observation that p75 NTR seems to be essential for the diff erentiation of neural precursor cells activated with BDNF in the absence of EGF [114] .
Early neurosphere cell studies (non-clonal) indicated that EGF had to be removed from the cultures in order to see a NT-mediated eff ect on diff erentiation [115] . In these studies, both BDNF and NGF induced neuronal diff erentiation, while removal of EGF led to astroglial diff erentiation. Th e more recent study by Benoit et al. [116] from the same laboratory is in agreement with our observation (unpublished) and shows expression of p75 NTR and all TRK (A, B and C) receptors for NGF, BDNF, and NT-3 on neurosphere cells, confi rming and extending previous data [115] . In population studies on neurosphere cells they had previously demonstrated the potent diff erentiation eff ects of both BDNF and NGF when EGF, the primary stimulus, was removed before the addition of these two NTs [115, 116] . Removal of EGF from neurosphere cells resulted in cessation of cell proliferation and pronounced astrocytic (glial fi brillary acidic protein positive) diff erentiation. Neuronal (neurofi lament positive) and oligodendroglial (galactocerebroside positive) cells appeared in cultures treated with NTs. Treatment with NGF resulted in bipolar neuronal cells and stimulation by BDNF led to multipolar neuronal cells while treatment with NT-3 resulted in bipolar neuronal cells and oligodendrocytes (galactocerebroside positive). Upon NGFmediated neuronal diff erentiation neuronal cells expressed ChAT+ and, to a lesser degree, tyrosine hydroxylase. During diff erentiation into astrocytes and neurons, the TRKB receptor is rather upregulated and the TRKC receptor is downregulated while the TRKA receptor remains at a relatively high expression level. In contrast, diff erentiation into oligodendrocytes seems to follow a NT-3/TRKC-dependent mechanism. Although several groups have shown that various NTs support survival of oligodendrocytes, NT-3 seems to be the major NT (in addition to other neurotrophic factors such as ciliary neurotrophic factor) responsible for directing NSCs into oligodendroglial cells. Th ese studies demonstrate that NTs infl uence the fates of these multipotential precursor cells [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] .
Considering clonal single NSC growth, it has been shown that withdrawal of EGF leads to time-dependent eff ects of both BDNF and NGF changing both gross colony morphology and lineage expression. BDNF and NGF show no eff ects on cell proliferation (if NSCs are cultured with EGF and BDNF or NGF) when compared to EGF controls and removal of EGF is permissive for the diff erentiating eff ects of BDNF and NGF. Th ese data also indicate that isolated neurosphere cells that grow in EGF have about 50% tri-lineage cells when stimulated with either BDNF or NGF for 14 days. While BDNF acts immediately, NGF eff ects can be seen at later points only. Th is could indicate that NGF works on a cell type that is less diff erentiated, or alternatively that these NTs have diff erential eff ects on inducing more NT receptors in diff erent cell classes. Th ese data further indicate that the majority of EGF neurosphere clones have NT-dependent tri-lineage potential. Removal of EGF with subsequent addition of BDNF or NGF results in an increase in neuronal and astroglial cells, but not oligodendrocytes [116] . At this point it is important to note that diff erences in NT receptor expression levels and NT responsiveness by numerous groups could be due to diff erences in cell concentration or the addition of serum, a potent astroglial inducing entity [115, 116, 122, 123] . Th e actions of BDNF and NGF on EGF-responsive clonal neurosphere diff erentiation are most probably due to induced diff erentiation, and not cell survival or proliferation. Th e enhanced total proliferation within the colonies is not the mechanism for increased neuronal or astroglial lineages. However, without the capacity to individually map all cells in a colony, the possibility of selected outgrowth of one cell population with a diminishment in another population cannot be ruled out. Th us, these data cannot absolutely rule out diff erentiation, proliferation, or survival eff ects on colony subsets. EGF maintains neurosphere cells with a predominantly primitive phenotype (nestin positive, lineage marker negative) and the continued presence of EGF appears to block the action of NTs on diff erentiation. Removal of EGF and the addition of NTs lead to lineage channeling toward neural and glial lineages without an eff ect on cell proliferation. Th ese data suggest a model of sequential growth factor action on neural progenitors with EGF acting as a proliferation and survival factor and NTs inducing diff erentiation while maintaining the neurosphere colonies' proliferation over time. 
Clinical Signifi cance and Future Directions
Understanding the physiological function of APP would allow us to gain insight into the molecular mechanisms behind the pathogenesis of AD. Such information would facilitate the development of novel therapeutic and even prophylactic strategies for the treatment of AD. Various studies have demonstrated a new role for APP in mediating the neurogenesis of progenitor cells within the hippocampus and SVZ of the adult brain. Th is has implications in the use of autologous stem cell replacement therapies in the repair of the adult CNS in AD patients in the near future. Current AD therapy serves only to reduce the degree of impairment and improve the quality of lives of patients. But the disease cannot be prevented or cured [13, 14, 124, 125] . Th e demonstration of active adult neurogenesis has since opened possibilities of repairing the mature CNS after degenerative neurological diseases like AD. Ongoing research promises a bright future for the clinical application of NSC strategies in neuro-replacement therapy for AD patients, and may potentially reverse the progression of the disease. Embryonic neural precursor cells provide an ideal alternative for transplantation in neurodegenerative diseases such as AD, as they can be expanded in culture, thus avoiding many of the practical obstacles that limit the application of transplanting primary neurons. It has already been shown that human NSCs transplanted into aged rat brains can diff erentiate into neural cells and signifi cantly improve the cognitive functions of animals, further pointing to NSCs as a promising candidate for neuroreplacement therapies [100, 103, 104] .
Conclusion
AD is a neurodegenerative disorder that currently affects nearly 2% of the population in industrialized countries. Th e risk of AD increases dramatically in individuals beyond the age of 70 and it is predicted that its incidence will increase threefold within the next 50 years. Brain regions involved in learning and memory processes, including the temporal and frontal lobes (the entorhinal cortex, hippocampus, basal forebrain and amygdala), are reduced in size in AD patients as a result of the degeneration of synapses and death of neurons. NSCs, with the capacity to self-renew and to produce the major cell types of the brain, exist in the developing and adult CNS. Th eir exact function and distribution is currently being assessed, but they represent an interesting cell population which may be used to study factors important for the diff erentiation of neurons, astrocytes and oligodendrocytes. Th ere have been reports recently of the eff ects of NSC transplantation that attempt to obtain functional recovery from CNS damage and recent evidence suggests that NSCs may be a suitable source for the treatment of neurological diseases such as AD or Parkinson's disease. With an eye towards the development of NSCs replacement therapies, it is important to investigate the migration profi le of NT-diff erentiated neurons and monitor the success of subsequent integrations into existing neuronal circuitries. Th e present review aims at gaining more insight into the functional role of the NTs on neurogenesis. Data indicate that NGF in particular may play a pivotal role in AD and the control of NSCs proliferation and diff erentiation. Loss of NGF functions may contribute to the progression of AD as impairment of neurogenesis is suffi cient to deteriorate learning and memory. A promising approach for the treatment of AD is the application of NGF as a potential remedy. However, delivering NGF to the brain in an appropriate manner is still challenging because NGF does not cross the blood-brain barrier when applied peripherally. Even NGF causes intolerable side eff ects (including pain) if administered into the brain ventricular system. Recent experiments show that intranasal administration of NGF rescues recognition memory defi cits in an anti-NGF transgenic mouse model which shows typical features of AD [49] . In addition, a brain site-specifi c gene delivery method provides suffi cient quantities of NGF to support neuronal survival at restricted sites to avoid adverse side eff ects. A recent phase-I clinical trial of NGF gene therapy for AD already provides promising data [126, 127] . In conclusion, NGF has been implicated in several new functions in the CNS, but much work remains to be done to explore the specifi c cross-talk between the NGF and APP systems and their specifi c role in neurogenesis. Such knowledge may then open new avenues for the treatment of neurodegenerative diseases such as AD.
